Zynex, Inc. (NasdaqGS:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced its Board of Directors (the "Board") has initiated a process to evaluate potential strategic alternatives to maximize shareholder value. As part of the process, the Board will evaluate, together with its advisors, a range of potential strategic alternatives which may include, any take private offers, a sale, merger or other business combination, a divestiture, a recapitalization, or other strategic transactions, or continuing to operate as a public, independent company. The Board has retained Cantor Fitzgerald & Co.

as its financial advisor, and Goodwin Procter LLP as its legal advisor to assist with this review process. "With continued strong financial performance including, greater than 170% revenue growth over the last four years, increased profit margins and cash flow positive operations and a strong balance sheet, we believe we are in a strong financial and operating position, yet our stock continues to trade well below a comparable industry value," said Thomas Sandgaard, President and CEO. "The Board believes that it is in the interests of our stockholders to explore strategic alternatives.

Regardless of the outcome, the entire organization will remain committed to growing our business and improving the lives of our patients". The Board has not set a timetable for the conclusion of this review, nor has it made any definitive decisions relating to potential strategic alternatives at this time. There can be no assurance that the review will result in any transaction or other strategic change or outcome.

The Company does not intend to comment further until it determines that further disclosure is appropriate or necessary.